Skip to main content
Erschienen in: Journal of General Internal Medicine 1/2012

01.01.2012

Use of a Pharmaceutically Adulterated Dietary Supplement, Pai You Guo, Among Brazilian-Born Women in the United States

verfasst von: Pieter A. Cohen, MD, Carly Benner, BA, Danny McCormick, MD, MPH

Erschienen in: Journal of General Internal Medicine | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

ABSTRACT

BACKGROUND

Pai You Guo is a weight loss supplement manufactured in China and adulterated with the banned pharmaceutical products sibutramine and phenolphthalein. The US Food and Drug Administration (FDA) announced a voluntary recall of Pai You Guo in 2009, yet clinicians have noted its continued use among Brazilian-born women in Massachusetts.

OBJECTIVE

To assess prevalence of Pai You Guo use, associated side effects, modes of acquisition, and impact of FDA regulatory action on these outcomes.

DESIGN

Cross-sectional study using an anonymous questionnaire.

PARTICIPANTS

Women ≤60 years of age, born in Brazil who attended one primary care clinic or one of six churches in Massachusetts.

MAIN MEASURES

Prevalence of use, how users first heard about the product, location of purchase, associated side effects, patterns of use before and after the FDA recall.

KEY RESULTS

Twenty-three percent (130/565) of respondents reported using Pai You Guo. In multivariate analysis, obesity (adj OR 3.7, p-value <0.001) and lack of insurance (adj OR 2.6, p-value 0.005) were associated with use. The majority of users (85%) reported at least one side effect. Dry mouth (59%), anxiety (29%), and insomnia (26%) were most commonly reported adverse effects. Nearly thirty-percent of users (38/130) purchased Pai You Guo from local stores and 9% (11/130) purchased it over the Internet. The majority of respondents (79/130; 61%) purchased Pai You Guo after the FDA recall. No respondent was aware of the FDA recall.

CONCLUSIONS

Use of this pharmaceutically adulterated supplement is common among Brazilian-born women in Massachusetts. The FDA alerts and recall did not appear to decrease its use.
Literatur
1.
Zurück zum Zitat Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235–41.PubMedCrossRef Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235–41.PubMedCrossRef
2.
Zurück zum Zitat Pillitteri JL, Shiffman S, Rohay JM, Harkins AM, Burton SL, Wadden TA. Use of dietary supplements for weight loss in the United States: Results of a national survey. Obesity. 2008;16(4):790–96.PubMedCrossRef Pillitteri JL, Shiffman S, Rohay JM, Harkins AM, Burton SL, Wadden TA. Use of dietary supplements for weight loss in the United States: Results of a national survey. Obesity. 2008;16(4):790–96.PubMedCrossRef
3.
Zurück zum Zitat Blanck HM, Serdula MK, Gillespie C, et al. Use of nonprescription dietary supplements for weight loss is common among Americans. J Am Diet Assoc. 2007;107(3):441–7.PubMedCrossRef Blanck HM, Serdula MK, Gillespie C, et al. Use of nonprescription dietary supplements for weight loss is common among Americans. J Am Diet Assoc. 2007;107(3):441–7.PubMedCrossRef
4.
Zurück zum Zitat Cohen PA. American roulette—contaminated dietary supplements. N Engl J Med. 2009;361(16):1523–5.PubMedCrossRef Cohen PA. American roulette—contaminated dietary supplements. N Engl J Med. 2009;361(16):1523–5.PubMedCrossRef
5.
Zurück zum Zitat Tang MH, Chen SP, Ng SW, Chan AY, Mak TW. Case series on a diversity of illicit weight-reducing agents: from the well known to the unexpected. Br J of Pharmacol. 2011;71(2):250–3.CrossRef Tang MH, Chen SP, Ng SW, Chan AY, Mak TW. Case series on a diversity of illicit weight-reducing agents: from the well known to the unexpected. Br J of Pharmacol. 2011;71(2):250–3.CrossRef
13.
Zurück zum Zitat US Food and Drug Administration. Laxative Drug Products for Over-the-Counter Human Use; Proposed Amendment to the Tentative Final Monograph. Notice of proposed rulemaking. Fed Regist. 1997 62(169):46223–26. US Food and Drug Administration. Laxative Drug Products for Over-the-Counter Human Use; Proposed Amendment to the Tentative Final Monograph. Notice of proposed rulemaking. Fed Regist. 1997 62(169):46223–26.
14.
Zurück zum Zitat (Forensic Chemistry Center, US Food and Drug Administration, Cincinnati, OH). Conversation with: Pieter Cohen (Department of Internal Medicine, Cambridge Health Alliance, Somerville, MA). 2011 Apr 8. (Forensic Chemistry Center, US Food and Drug Administration, Cincinnati, OH). Conversation with: Pieter Cohen (Department of Internal Medicine, Cambridge Health Alliance, Somerville, MA). 2011 Apr 8.
15.
Zurück zum Zitat (Westenberger BJ, Division of Pharmaceutical Analysis, US Food and Drug Administration, St. Louis, Missouri). Conversation with: Pieter Cohen (Department of Internal Medicine, Cambridge Health Alliance, Somerville, MA). 2011 May 3. (Westenberger BJ, Division of Pharmaceutical Analysis, US Food and Drug Administration, St. Louis, Missouri). Conversation with: Pieter Cohen (Department of Internal Medicine, Cambridge Health Alliance, Somerville, MA). 2011 May 3.
18.
Zurück zum Zitat Cohen PA, McCormick D, Casey C, Dawson GF, Hacker KA. Imported compounded diet pill use among Brazilian women immigrants in the United States. J Immigr Minor Health. 2009;11(3):229–36.PubMedCrossRef Cohen PA, McCormick D, Casey C, Dawson GF, Hacker KA. Imported compounded diet pill use among Brazilian women immigrants in the United States. J Immigr Minor Health. 2009;11(3):229–36.PubMedCrossRef
20.
Zurück zum Zitat James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905.PubMedCrossRef James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905.PubMedCrossRef
21.
Zurück zum Zitat Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev. 2008;9(4):378–87.PubMedCrossRef Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev. 2008;9(4):378–87.PubMedCrossRef
22.
Zurück zum Zitat Nguyen MH, Ormiston T, Kurani S, Woo DK. Amphetamine lacing of an Internet-marketed neutraceutical. Mayo Clin Proc. 2006;81(12):1627–9.PubMedCrossRef Nguyen MH, Ormiston T, Kurani S, Woo DK. Amphetamine lacing of an Internet-marketed neutraceutical. Mayo Clin Proc. 2006;81(12):1627–9.PubMedCrossRef
23.
Zurück zum Zitat Cohen PA. Imported fenproporex-based diet pills from Brazil: a report of two cases. J Gen Intern Med. 2009;24(3):430–3.PubMedCrossRef Cohen PA. Imported fenproporex-based diet pills from Brazil: a report of two cases. J Gen Intern Med. 2009;24(3):430–3.PubMedCrossRef
Metadaten
Titel
Use of a Pharmaceutically Adulterated Dietary Supplement, Pai You Guo, Among Brazilian-Born Women in the United States
verfasst von
Pieter A. Cohen, MD
Carly Benner, BA
Danny McCormick, MD, MPH
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Journal of General Internal Medicine / Ausgabe 1/2012
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-011-1828-0

Weitere Artikel der Ausgabe 1/2012

Journal of General Internal Medicine 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.